Here are 1-3 brief analogies for Indaptus Therapeutics (INDP):

• Like a very early-stage Bristol Myers Squibb or Merck, but specializing in broad-spectrum immunotherapies for both cancer and viral infections.
• Imagine a biotech with the ambition of Gilead Sciences, but focused on a novel immunotherapy to tackle both viral diseases and various cancers.

Indaptus Therapeutics (INDP) major products:

• Decoy20: A lead clinical candidate, this anti-cancer and anti-viral immunotherapy product is currently in Phase 2 clinical trials for treating various tumors and viral infections like chronic hepatitis B and HIV.

Indaptus Therapeutics (INDP) is a clinical-stage biotechnology company primarily focused on the research and development of anti-cancer and anti-viral immunotherapy products. Its lead candidate, Decoy20, is currently in Phase 2 clinical trials.

As a company in the clinical development stage, Indaptus Therapeutics does not yet have any commercialized products available for sale. Therefore, the company does not currently have "major customers" in the traditional sense of entities or individuals purchasing its products or services.

• Catalent Pharma Solutions (CTLT)
• Cambrex

Jeffrey A. Meckler, Co-Chief Executive Officer

Jeffrey Meckler brings over 30 years of financial and healthcare leadership experience to Indaptus Therapeutics. He most recently served as the CEO of Intec Pharma and previously as CEO of Cocrystal Pharma, where he transformed it into a clinical and development company. Meckler also acted as a director and interim CEO of Cypress Bioscience, which was later acquired by Royalty Pharma. His career began at Pfizer, where he was involved in acquisitions and divestitures. He has also held directorial roles at several companies, including QLT, Inc., Cocrystal Pharma, and currently serves as a director and former Chairman of Travere Therapeutics.

David E. Lazar, Co-Chief Executive Officer and Chairman of the Board

David E. Lazar was appointed Co-Chief Executive Officer and Chairman of the Board of Indaptus Therapeutics on December 23, 2025, in conjunction with a $6 million securities purchase agreement. He has previously served as CEO of Kala Bio Inc. and Novabay Pharmaceuticals. Under the securities purchase agreement, Lazar has the right to recommend three individuals to the Indaptus board.

Nir Sassi, Chief Financial Officer

Nir Sassi possesses a broad skillset encompassing management, corporate finance, due diligence, accounting, and financial analysis. Before joining Indaptus, he spent 11 years at Intec Pharma, where he advanced from Vice President of Finance to Chief Financial Officer. Earlier in his career, Sassi worked for eight years as a Senior Manager at PricewaterhouseCoopers Israel, including a two-year relocation to their New York office.

Michael J. Newman, Ph.D., Founder and Chief Scientific Officer

Dr. Michael Newman is a founder of Indaptus Therapeutics and serves as its Chief Scientific Officer. He has over 35 years of experience in oncology drug discovery and early development within academia, pharmaceutical, and biotechnology companies. Newman was the Founder and CEO of Decoy Biosystems, where he developed the core technology that forms the foundation of Indaptus. He has also consulted for approximately 35 companies, offering expertise in target identification, R&D management, fundraising, and licensing.

Walt A. Linscott, Esq., Chief Operating Officer

Walt Linscott brings over three decades of global leadership, entrepreneurial, and professional experience to his role as Chief Operating Officer at Indaptus, with extensive expertise in business development, operations, regulatory affairs, and transactions within the Life Sciences sector. Prior to his current role, he was the Chief Business Officer at Indaptus and previously held the same position at Intec Pharma. Linscott is also a founding executive member of Oxford Strategic Alliance, a firm focused on multinational business development. He co-founded Treiber Therapeutics, an anti-viral focused venture, where he served as President, COO, and General Counsel.

The key risks for Indaptus Therapeutics (INDP) primarily stem from its status as a clinical-stage biotechnology company with a single lead product candidate.

1. Single-Asset Clinical-Stage Risk: Indaptus Therapeutics' entire valuation and future success are predominantly tied to the success of its lead product candidate, Decoy20. This presents a massive concentration risk, as any significant roadblock or failure of Decoy20 in clinical trials, particularly in Phase 2 and subsequent stages, would likely lead to a near-total loss of the company's value.
2. Significant Funding Needs and Dilution: The company faces substantial financial challenges, operating with a high cash burn rate and a very tight cash runway. As of late 2025, Indaptus Therapeutics had limited cash and cash equivalents, which were expected to fund operations only into the first quarter of 2026 without additional capital. This necessitates immediate and often highly dilutive equity financing rounds, evidenced by recent convertible notes and warrants that pose future overhang and dilution risks for shareholders.
3. Clinical Trial Failure and Regulatory Hurdles: As with all clinical-stage biotechnology companies, Indaptus Therapeutics faces inherent and significant risks associated with the drug development process. Decoy20 is currently in Phase 2 trials, and there is no guarantee of success in these or subsequent pivotal trials (e.g., Phase 3). Patient enrollment in some trials has been paused for further efficacy analysis, and initial results have shown mixed outcomes, with some participants experiencing stable disease and others disease progression. Additionally, navigating complex regulatory approval processes poses ongoing challenges and uncertainties.

Indaptus Therapeutics, Inc. (symbol: INDP) is a clinical biotechnology company developing Decoy20 for various anti-cancer and anti-viral immunotherapy applications. The addressable markets for their main products or services are sizable across several indications:

• Lymphoma: The global lymphoma treatment market was valued at approximately USD 7.41 billion in 2024 and is projected to reach USD 11.97 billion by 2030. Another estimate for the global lymphoma therapeutics market size was USD 7.85 billion in 2024, projected to grow to about USD 17.75 billion by 2034. North America held the largest share of this market, accounting for 49.0% of the revenue in 2024.
• Hepatocellular Carcinoma (Liver Cancer): The global liver cancer drug market size was estimated at USD 3.67 billion in 2024 and is projected to reach USD 9.81 billion by 2030. Another report indicated the global hepatocellular carcinoma (HCC) treatment market was valued at USD 4.3 billion in 2025 and is projected to reach USD 33.8 billion by 2035. In 2024, North America was the leading revenue-generating region, accounting for 39.4% of the global market.
• Colorectal Cancer: The global colorectal cancer therapeutics market size was estimated at USD 11.5 billion in 2022 and is expected to grow to USD 16.7 billion by 2030. Another assessment put the global colorectal cancer market size at USD 22.28 billion in 2024, with a projection to reach USD 30.10 billion by 2033. North America held a dominant position in the global colorectal cancer therapeutics market, with a 42.6% revenue share in 2022. The total colorectal cancer market size in the seven major markets (7MM: United States, EU4, United Kingdom, and Japan) was approximately USD 13 billion in 2023.
• Pancreatic Tumors (Pancreatic Cancer): The global pancreatic cancer market size was estimated at USD 3.25 billion in 2025 and is projected to surpass USD 10.25 billion by 2034. Another source states the global pancreatic cancer treatment market size was USD 3.82 billion in 2025, projected to reach USD 14.43 billion by 2034. North America was the largest market in 2024, with a global share of 39.27% in the pancreatic cancer treatment market.
• Chronic Hepatitis B Virus: The chronic Hepatitis B (CHB) market across the seven major markets (7MM: United States, EU4, United Kingdom, and Japan) was valued at approximately USD 1.60 billion in 2025 and is expected to expand to USD 3.2 billion by 2034. The United States is expected to be the largest contributor, accounting for approximately 72% of the total 7MM market share in 2024. Furthermore, the global hepatitis B therapeutics market size was USD 2.48 billion in 2025 and is projected to grow to USD 6.66 billion by 2034. North America dominated this market with a 52.31% share in 2025.
• Human Immunodeficiency Virus (HIV) Infection: The global HIV drugs market size was USD 38.27 billion in 2025 and is projected to grow to USD 66.09 billion by 2034. The global human immunodeficiency virus therapeutics market size was valued at USD 39 billion in 2024 and is projected to reach USD 54.8 billion by 2034. North America dominated the HIV drugs market with a 70.71% market share in 2025. The U.S. alone generated approximately USD 14.5 billion in the North American HIV therapeutics market in 2024.

Indaptus Therapeutics, Inc. (INDP), a clinical-stage biotechnology company, is currently focused on advancing its lead immunotherapy candidate, Decoy20. As a pre-revenue company, its future revenue growth over the next 2-3 years will be primarily driven by key developments in its clinical pipeline and strategic initiatives.

Here are the expected drivers of future revenue growth:

1. Progression and Success in Clinical Trials for Decoy20: The most significant driver for Indaptus Therapeutics' future revenue growth is the successful advancement of its lead clinical candidate, Decoy20, through its Phase 1 clinical trial and into later-stage trials (Phase 2 and Phase 3). Positive clinical data, demonstrating efficacy and a favorable safety profile across various tumor types such as lymphoma, hepatocellular, colorectal, and pancreatic cancers, as well as chronic hepatitis B and HIV infections, is crucial for eventual regulatory approval and commercialization. The company has reported promising early signs of clinical benefit, including stable disease in some patients within its ongoing Phase 1 trial.

2. Expansion into Combination Therapies with Decoy20: A key driver for broadening Decoy20's market potential is its development as a combination therapy. Indaptus Therapeutics has a clinical supply agreement with BeiGene to evaluate Decoy20 in conjunction with BeiGene's anti-PD-1 antibody, tislelizumab, for the treatment of advanced solid tumors. Successful outcomes in these combination studies could lead to enhanced therapeutic options, increased market adoption, and a larger addressable patient population upon regulatory approval.

3. Broadening Decoy20's Therapeutic Indications and Geographic Reach: Indaptus is actively exploring multiple indications for Decoy20, including its initial focus on various cancers and viral infections. The company has also secured new patents in China, Japan, and Israel, specifically covering Decoy bacteria compositions for the prevention or treatment of Hepatitis B virus (HBV) and human immunodeficiency virus (HIV). Furthermore, receiving Clinical Trial Authorization from Health Canada allows for the expansion of its ongoing U.S. clinical trial to Canadian sites, which is expected to broaden patient recruitment and accelerate the clinical research program. These expansions in therapeutic applications and geographical markets will be vital for future revenue streams.

Share Issuance

• Indaptus Therapeutics issued 2,109,383 shares of common stock and warrants to purchase an equal number of shares in a January 2025 private placement, for a combined consideration of $1.065 per share and warrant.
• In December 2025, Indaptus entered into a $6 million securities purchase agreement with investor David E. Lazar for the issuance of non-voting convertible preferred stock, which stockholders later approved to convert into 111 million shares of common stock in February 2026.
• The company executed a 1-for-28 reverse stock split effective June 26, 2025, reducing outstanding shares from approximately 16 million to about 572 thousand.

Inbound Investments

• David E. Lazar made a $6 million investment in Indaptus Therapeutics in December 2025 through a securities purchase agreement, acquiring non-voting convertible preferred stock.

Capital Expenditures

• Indaptus Therapeutics had expected that its cash and cash equivalents, combined with proceeds from the January 2025 financing, would fund capital expenditure requirements into the second quarter of 2025.
• The company reported $0 in capital expenditures in Q4 2021.